MR-T2-weighted signal intensity: a new imaging biomarker of prostate cancer aggressiveness

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Prostate cancer (PCa) is the most common solid neoplasm in males and a major cause of cancer-related death. Behaviour of PCa is dichotomous, as patients may either have an indolent clinical course or rapidly progress towards metastatic disease. Unfortunately, biopsy Gleason score (GS) may fail to predict cancer aggressiveness; tumour heterogeneity and inaccurate sampling during biopsy are major causes of underestimation. As a consequence, this frequently results in over-treatment, i.e. low-risk patients overcautiously undergo radical prostatectomy or radiotherapy, frequently with devastating side-effects. Some patients with PCa could be offered a more conservative approach if it were possible to predict patient risk confidently, especially in subjects lying in the grey zone of intermediate risk (i.e. GS = 7), which are in the majority. Recent studies have demonstrated that magnetic resonance (MR) imaging may help improve risk stratification in patients with PCa, providing imaging biomarkers of cancer aggressiveness. The aim of this study is to implement an automatic algorithm pipeline to discriminate different risks of progression from T2-weighted (T2-w) MR imaging. The obtained results confirm that T2-w signal intensity, together with other imaging biomarkers, may represent a new non-invasive approach to assess cancer aggressiveness, potentially helping to plan personalised treatments, and thus dramatically limiting over-diagnosis and over-treatment risks, and reducing the costs for the national healthcare system.

Original languageEnglish
Pages (from-to)130-134
Number of pages5
JournalComputer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization
Volume4
Issue number3-4
DOIs
Publication statusPublished - Jul 3 2016

Fingerprint

Biomarkers
Magnetic resonance
Magnetic Resonance Spectroscopy
Imaging techniques
Prostatic Neoplasms
Neoplasm Grading
Biopsy
Neoplasms
Magnetic Resonance Imaging
Radiotherapy
Tumor Biomarkers
Prostatectomy
Prostate Cancer, Hereditary, 7
Tumors
Therapeutics
Pipelines
Sampling
Delivery of Health Care
Costs and Cost Analysis
Costs

Keywords

  • endorectal MR imaging
  • prostate cancer
  • T2-weighted MR images
  • tumour aggressiveness

ASJC Scopus subject areas

  • Biomedical Engineering
  • Radiology Nuclear Medicine and imaging
  • Computational Mechanics
  • Computer Science Applications

Cite this

@article{8b3a9432b26f4c489f4b79fffcdd4039,
title = "MR-T2-weighted signal intensity: a new imaging biomarker of prostate cancer aggressiveness",
abstract = "Prostate cancer (PCa) is the most common solid neoplasm in males and a major cause of cancer-related death. Behaviour of PCa is dichotomous, as patients may either have an indolent clinical course or rapidly progress towards metastatic disease. Unfortunately, biopsy Gleason score (GS) may fail to predict cancer aggressiveness; tumour heterogeneity and inaccurate sampling during biopsy are major causes of underestimation. As a consequence, this frequently results in over-treatment, i.e. low-risk patients overcautiously undergo radical prostatectomy or radiotherapy, frequently with devastating side-effects. Some patients with PCa could be offered a more conservative approach if it were possible to predict patient risk confidently, especially in subjects lying in the grey zone of intermediate risk (i.e. GS = 7), which are in the majority. Recent studies have demonstrated that magnetic resonance (MR) imaging may help improve risk stratification in patients with PCa, providing imaging biomarkers of cancer aggressiveness. The aim of this study is to implement an automatic algorithm pipeline to discriminate different risks of progression from T2-weighted (T2-w) MR imaging. The obtained results confirm that T2-w signal intensity, together with other imaging biomarkers, may represent a new non-invasive approach to assess cancer aggressiveness, potentially helping to plan personalised treatments, and thus dramatically limiting over-diagnosis and over-treatment risks, and reducing the costs for the national healthcare system.",
keywords = "endorectal MR imaging, prostate cancer, T2-weighted MR images, tumour aggressiveness",
author = "V. Giannini and A. Vignati and S. Mirasole and S. Mazzetti and F. Russo and M. Stasi and D. Regge",
year = "2016",
month = "7",
day = "3",
doi = "10.1080/21681163.2014.910476",
language = "English",
volume = "4",
pages = "130--134",
journal = "Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization",
issn = "2168-1163",
publisher = "Taylor and Francis Ltd.",
number = "3-4",

}

TY - JOUR

T1 - MR-T2-weighted signal intensity

T2 - a new imaging biomarker of prostate cancer aggressiveness

AU - Giannini, V.

AU - Vignati, A.

AU - Mirasole, S.

AU - Mazzetti, S.

AU - Russo, F.

AU - Stasi, M.

AU - Regge, D.

PY - 2016/7/3

Y1 - 2016/7/3

N2 - Prostate cancer (PCa) is the most common solid neoplasm in males and a major cause of cancer-related death. Behaviour of PCa is dichotomous, as patients may either have an indolent clinical course or rapidly progress towards metastatic disease. Unfortunately, biopsy Gleason score (GS) may fail to predict cancer aggressiveness; tumour heterogeneity and inaccurate sampling during biopsy are major causes of underestimation. As a consequence, this frequently results in over-treatment, i.e. low-risk patients overcautiously undergo radical prostatectomy or radiotherapy, frequently with devastating side-effects. Some patients with PCa could be offered a more conservative approach if it were possible to predict patient risk confidently, especially in subjects lying in the grey zone of intermediate risk (i.e. GS = 7), which are in the majority. Recent studies have demonstrated that magnetic resonance (MR) imaging may help improve risk stratification in patients with PCa, providing imaging biomarkers of cancer aggressiveness. The aim of this study is to implement an automatic algorithm pipeline to discriminate different risks of progression from T2-weighted (T2-w) MR imaging. The obtained results confirm that T2-w signal intensity, together with other imaging biomarkers, may represent a new non-invasive approach to assess cancer aggressiveness, potentially helping to plan personalised treatments, and thus dramatically limiting over-diagnosis and over-treatment risks, and reducing the costs for the national healthcare system.

AB - Prostate cancer (PCa) is the most common solid neoplasm in males and a major cause of cancer-related death. Behaviour of PCa is dichotomous, as patients may either have an indolent clinical course or rapidly progress towards metastatic disease. Unfortunately, biopsy Gleason score (GS) may fail to predict cancer aggressiveness; tumour heterogeneity and inaccurate sampling during biopsy are major causes of underestimation. As a consequence, this frequently results in over-treatment, i.e. low-risk patients overcautiously undergo radical prostatectomy or radiotherapy, frequently with devastating side-effects. Some patients with PCa could be offered a more conservative approach if it were possible to predict patient risk confidently, especially in subjects lying in the grey zone of intermediate risk (i.e. GS = 7), which are in the majority. Recent studies have demonstrated that magnetic resonance (MR) imaging may help improve risk stratification in patients with PCa, providing imaging biomarkers of cancer aggressiveness. The aim of this study is to implement an automatic algorithm pipeline to discriminate different risks of progression from T2-weighted (T2-w) MR imaging. The obtained results confirm that T2-w signal intensity, together with other imaging biomarkers, may represent a new non-invasive approach to assess cancer aggressiveness, potentially helping to plan personalised treatments, and thus dramatically limiting over-diagnosis and over-treatment risks, and reducing the costs for the national healthcare system.

KW - endorectal MR imaging

KW - prostate cancer

KW - T2-weighted MR images

KW - tumour aggressiveness

UR - http://www.scopus.com/inward/record.url?scp=84981363507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981363507&partnerID=8YFLogxK

U2 - 10.1080/21681163.2014.910476

DO - 10.1080/21681163.2014.910476

M3 - Article

AN - SCOPUS:84981363507

VL - 4

SP - 130

EP - 134

JO - Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization

JF - Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization

SN - 2168-1163

IS - 3-4

ER -